Allogeneic transplantation for chronic lymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Transplantation Immunology

Background:

• Chronic lymphocytic leukemia (CLL) typically behaves indolently, but 20% of patients have aggressive disease unresponsive to standard therapies.
• Poor-risk CLL is defined by specific criteria including refractoriness to purine analogs, early relapse, or p53 lesions.
• Allogeneic stem cell transplantation (SCT) offers curative potential but historically carries high transplant-related mortality (TRM).

Purpose of the Study:

• To evaluate the role and challenges of allogeneic SCT in managing aggressive Chronic Lymphocytic Leukemia (CLL).
• To highlight the impact of reduced intensity conditioning (RIC) regimens on SCT outcomes in CLL.
• To identify key complications and failure points following RIC allo-HCT for CLL.

Main Methods:

• Review of allogeneic SCT outcomes in Chronic Lymphocytic Leukemia (CLL) patients, focusing on reduced intensity conditioning (RIC) regimens.
• Analysis of major complications including graft-versus-host disease (GVHD), graft rejection, infection, and disease relapse.
• Assessment of the prognostic significance of minimal residual disease (MRD) quantification post-transplant.

Main Results:

• Reduced intensity conditioning (RIC) has decreased short-term morbidity and mortality associated with allogeneic SCT in CLL.
• Disease relapse remains the primary cause of treatment failure after RIC allo-HCT in CLL.
• Graft-versus-leukemia (GVL) activity is the critical therapeutic principle of allo-SCT in CLL.
• Chronic GVHD, graft rejection, and infections are significant complications impacting quality of life and treatment success.

Conclusions:

• Allogeneic SCT, particularly with RIC, is a viable curative option for poor-risk CLL patients.
• Minimizing disease relapse and managing complications like GVHD are crucial for improving long-term survival after RIC allo-HCT.
• Sensitive minimal residual disease (MRD) monitoring is essential for prognostication post-transplant in CLL.